U.S. COMPANY FILING
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
Filing text preview
AstraZeneca and Ionis announced that the CARDIO-TTRansform Phase III trial of Wainua (eplontersen) in ATTR-CM did not meet its primary efficacy endpoint of composite CV mortality and recurrent CV events. Safety was consistent. A prespecified subgroup showed nominally significant benefit in monotherapy, but no effect with stabilizer. Full results will be presented at ESC Congress August 2026.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record